2011 European Multidisciplinary Cancer Congress

Prostate Cancer

International Prostate Cancer Studies Report Inroads in Managing Bone Metastases

Treatment and prevention of bone metastases in patients with prostate cancer is coming of age, according to several studies presented at the European Multidisciplinary Cancer Congress (ECCO/ESMO/ESTRO...

Colorectal Cancer

Panitumumab Is Not Beneficial in KRAS Mutations: No Exceptions

The need to restrict treatment with panitumumab (Vectibix) to metastatic colorectal cancer patients with wild-type (normal) KRAS tumors was upheld in a study presented at the 2011 European Multidiscip...

Breast Cancer

T-DM1: Antibody Drug Conjugate Outperforms Standard Anti‑HER2 Therapy in Metastatic HER2-positive Breast Cancer

The investigational antibody-drug conjugate T-DM1 improved progression-free survival over standard chemotherapy with docetaxel plus trastuzumab (Herceptin) when given as first-line treatment of HER2-p...

Lung Cancer

NSCLC Studies: Bevacizumab/Pemetrexed Maintenance Improves Survival, KRAS Status Has No Impact on Outcomes with Sorafenib

Maintenance therapy with bevacizumab (Avastin) plus pemetrexed (Alimta) showed a modest improvement in progression-free survival vs bevacizumab alone in patients with advanced non–small cell lung canc...

Breast Cancer

Everolimus Overcomes Resistance to Hormonal Therapy in Advanced Breast Cancer

Adding everolimus (Afinitor) to exemestane in postmenopausal women with advanced breast cancer resistant to aromatase inhibitors significantly improved outcomes, according to the phase III BOLERO-2 tr...

Skin Cancer

‘Breakthrough’ Approach to Advanced Basal Cell Carcinoma via Inhibition of Hedgehog Pathway

The first-in-class Hedgehog pathway inhibitor vismodegib appears to be a successful treatment for advanced basal cell carcinoma, a disfiguring and debilitating disease, according to a pivotal multicen...

Issues in Oncology

Chemotherapy Generally Safe in Pregnancy

The diagnosis of cancer in a pregnant woman causes concerns for both the mother and her unborn child. But studies suggest that most chemotherapy regimens can be delivered with reasonable safety after ...

Issues in Oncology

Predictive Biomarker for Bevacizumab: Are We Getting Closer?

The need to identify a biomarker to guide treatment with bevacizumab (Avastin) is abundantly clear, and studies presented at the 2011 European Multidisciplinary Cancer Congress suggest this goal may b...

Colorectal Cancer

Aflibercept Improves Overall Survival in Patients with Metastatic Colorectal Cancer

The novel fusion protein aflibercept added to standard chemotherapy led to an overall survival benefit in a global phase III trial of second-line metastatic colorectal cancer, reported at the 2011 Eur...

Sarcoma

Researchers Find Remarkable Heterogeneity in Sarcomas

Does one size fit all for the treatment of sarcoma? The answer is a resounding “no,” according to Jean-Yves Blay, MD, Department of Medicine, Université Claude Bernard, and Unité INSERM (National Inst...

Issues in Oncology

Twitter Dominates Social Media Buzz at Stockholm Meeting

There was a time when clinical trial results were disseminated mainly through peer-reviewed journals that appeared in your mailbox. Computers and prompt reporting from medical conferences changed that...

Breast Cancer

Male Breast Cancer Differs from Breast Cancer in Women, but Little Data Informs Treatment

Although a rare occurrence, men do get breast cancer, and when they do, it has a distinct biology from that of female breast cancer. About 90% of cases most closely resemble postmenopausal female inva...

Head and Neck Cancer

Benefit of Panitumumab Seen Primarily in Patients with Recurrent or Metastatic Head and Neck Cancer and HPV-negative Tumors

The addition of panitumumab (Vectibix) to chemotherapy improved overall and progression-free survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck, but its ben...

Lung Cancer
Gynecologic Cancers
Colorectal Cancer
Hepatobiliary Cancer

Important Briefs from the 2011 European Multidisciplinary Cancer Congress

Nearly 16,000 people from 16 countries attended this year’s European Multidisciplinary Cancer Congress, held recently in Stockholm. The ASCO Post has featured several key reports from the meeting and ...

Breast Cancer

Changes in Receptor Status during Breast Cancer Progression Warrant Rebiopsies at Relapse and Metastasis

Oncologists should be aware that common clinical tumor markers (denoting hormonal and HER2 status) change as breast cancer progresses, because these changes can affect treatment selection. Estrogen re...

Advertisement

Advertisement



Advertisement